The 2022 Second Edition of GAMP 5 represents the most significant reframing of computer system validation philosophy since the original publication. The central message is direct: stop producing documentation for its own sake and start producing evidence that genuinely assures system fitness for intended use.
What Changed and What Stayed the Same
The fundamental lifecycle — plan, specify, build, test, release, operate — remains intact. What changed is the expected rigor at each stage. The Second Edition explicitly states that the amount of validation effort and documentation should be commensurate with risk to patient safety, product quality, and data integrity. A low-risk Category 3 infrastructure tool does not require the same validation package as a high-risk Category 5 custom application.
This sounds obvious. In practice, many organizations have been applying the same documentation template to every system regardless of risk — producing massive validation packages for low-risk tools while paradoxically under-documenting genuinely critical systems.
FDA Computer Software Assurance Alignment
FDA's 2022 Computer Software Assurance (CSA) guidance aligns directly with GAMP 5 Second Edition. Both emphasize critical thinking over documentation checklist completion, testing that is meaningful rather than exhaustive, and leveraging vendor-supplied documentation where appropriate rather than recreating it.
The practical implication: FDA inspectors are increasingly looking at the quality of your testing rationale rather than the volume of your test scripts. A well-reasoned risk-based test approach with clear acceptance criteria will satisfy an inspector more reliably than 400 test scripts that cover low-risk functionality no one has thought critically about.
What This Means for Existing Validated Systems
If your validated system portfolio was built under GAMP 5 First Edition principles, a formal gap assessment against Second Edition expectations is prudent — particularly if any of those systems are approaching periodic review cycles. The gap assessment should focus on whether your current risk assessments use meaningful risk criteria, whether your test coverage is rationale-driven, and whether your vendor assessment process leverages supplier quality data effectively.